Annals of Oncology APC and Open Access: ESMO's Flagship at a Competitive Price

Annals of Oncology has experienced a remarkable rise in influence over the past decade. Its impact factor has climbed from around 10 in 2015 to approximately 50 in 2024, driven by the journal's success in attracting practice-changing clinical trial results.

The journal's strength areas include:

• Phase III clinical trials in solid tumors, particularly breast cancer, lung cancer, and GI cancers
• ESMO Clinical Practice Guidelines, which shape oncology practice across Europe and increasingly worldwide
• Immunotherapy clinical data, including checkpoint inhibitor trials
• Precision oncology and biomarker-driven treatment studies
• Real-world evidence and health outcomes research in oncology
• ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and similar frameworks

Annals of Oncology published approximately 300-400 articles in 2024. The desk-rejection rate is high, estimated at 70-80%, reflecting its position as one of the most selective clinical oncology journals. The editors want clinical data that changes treatment algorithms or fundamentally shifts understanding of a disease.

The journal is particularly strong in European-led clinical trials. ESMO's membership and network across European cancer centers creates a natural pipeline of high-impact clinical oncology research.

Annals of Oncology is hybrid:

1. Subscription track (default, $0): Published behind the Elsevier paywall. ESMO members and institutional subscribers have access. No cost to the author.
2. Gold OA track ($4,000-$5,000): Immediate free access under a Creative Commons license.

ESMO has over 35,000 members worldwide, all of whom have Annals of Oncology access. Combined with institutional subscriptions at cancer centers and academic medical centers, the subscriber base is extensive. Subscription-track publication still reaches the core clinical oncology audience.

OA is particularly valuable for clinical practice guidelines and treatment algorithm papers. When ESMO guidelines are published OA, they're accessible to every oncologist globally, including those in low-resource settings without ESMO membership or institutional access. This broad reach directly affects patient care.

Annals of Oncology's position within Elsevier's agreement landscape is more favorable than some Elsevier titles:

Unlike Cell Press and Lancet titles, which are almost universally excluded from Elsevier transformative agreements, society journals published by Elsevier sometimes have different coverage terms. Annals of Oncology, as an ESMO journal published through Elsevier, may fall into a covered category in some institutional deals.

The key word is "may." Coverage is not guaranteed and varies by agreement. You must check with your library specifically about Annals of Oncology. Don't assume that a general Elsevier deal covers it, but also don't assume it's excluded like Cancer Cell or Lancet Oncology.

ESMO membership provides several benefits relevant to Annals of Oncology:

ESMO doesn't typically offer direct APC discounts tied to membership, but the society runs several programs that can help with publication costs:

• ESMO Translational Research Grants and Fellowships often include publication cost provisions.
• ESMO Congress abstract presenters who develop their work into full manuscripts may receive editorial encouragement and faster review, though not APC subsidies per se.
• ESMO Guidelines authors are typically covered for OA costs as part of the guidelines production process.

Elsevier's waiver framework applies to Annals of Oncology:

• Geographical pricing (GPOA): Elsevier's Geographical Pricing for Open Access provides reduced APCs for authors from lower-income countries. Discounts range from 25% to 100% depending on country tier.
• Hardship waivers: Case-by-case consideration for authors who can demonstrate financial need.
• No automatic Research4Life-style waivers: Elsevier's system is less automatic than Springer Nature's Research4Life framework. Discounts are calculated during the APC payment process based on institutional and geographic data.

For oncologists in low-resource settings studying cancers prevalent in their regions, the waiver system is essential. Cervical cancer researchers in sub-Saharan Africa or gastric cancer researchers in Southeast Asia should explore GPOA pricing before assuming the full APC applies.

For European-funded oncology research (ERC, Horizon Europe), Annals of Oncology is a natural choice. The journal's ESMO identity and European research base align with EU funder mandates, and the moderate APC makes compliance affordable.

For NIH-funded researchers, the green OA route works: publish via subscription, deposit the accepted manuscript in PMC after a 12-month embargo. The subscription track is free, making this the most economical compliance path.

• Tax: VAT applies in EU jurisdictions, adding 15-25%. For a European society journal with many European authors, this is a common additional expense.
• Embargo timing: The 12-month green OA embargo starts from the online publication date. Factor in production time when calculating your total timeline to public access.
• CONSORT and STROBE compliance: Annals of Oncology enforces reporting guideline adherence strictly. If your clinical trial report doesn't meet CONSORT standards at submission, the editors will flag it. Getting reporting right upfront saves revision cycles.
• Central figure quality: The journal expects publication-ready figures with consistent styling. Professional figure preparation costs $200-$500 if not handled in-house.
• Supplementary data volume: Phase III trial papers in Annals often have 10-20 supplementary tables and figures. Preparation time is significant.

Like the ADA Standards of Care in Diabetes Care, ESMO Clinical Practice Guidelines published in Annals of Oncology have outsized influence. These guidelines:

• Are used by oncologists across 168+ countries
• Are referenced by national health systems for treatment reimbursement decisions
• Include ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) ratings
• Are updated regularly as new evidence emerges

If your research generates evidence relevant to ESMO guideline updates, publishing in Annals of Oncology ensures the guideline authors see your data in the same journal where they publish their recommendations.

For clinical oncology researchers considering Annals of Oncology:

1. Check Elsevier agreement coverage. Your institutional deal may cover Annals of Oncology even if it doesn't cover Cell Press or Lancet titles. Ask your library specifically.
2. European-led clinical trial? Annals of Oncology is the natural home. ESMO identity, European reviewer base, and guideline alignment all favor it.
3. NIH-funded? The free green route (subscription + PMC after 12 months) works well and costs nothing.
4. Choosing between Annals and JCO? Consider geographic alignment, disease focus, and which society's guidelines your work informs. The APC difference is minimal.
5. Paper not quite Annals-tier? European Journal of Cancer or Clinical Cancer Research at similar price points are solid alternatives.

Practice-changing clinical oncology papers need impeccable trial design, clear primary endpoints, and conclusions that translate directly into treatment decisions. Annals editors will assess whether your findings move the needle for patients. Run a free readiness scan to check your manuscript's clinical narrative and statistical presentation before submitting.

For the latest fee schedule and author guidelines, visit the Annals of Oncology author page.